DocG DocG | AI-Powered Clinical Summaries
Sign In

Stay Current with Medical Literature

AI-powered clinical summaries delivered to your inbox 3 times per week. Evidence-based insights in 300 words, designed for busy physicians.

Sign Up

See What You Get

Subscribers receive email summaries and access to our interactive AI-powered article rankings.

Email Summary Example

RSV vaccine reduced RSV-related hospitalizations
In adults 60 years or older, a single RSV prefusion F vaccine dose greatly lowered RSV-related hospitalization, with very small absolute risk reduction.
*Pragmatic open-label randomized trial; Level 1b (OCEBM).

Citation

Lassen MCH, Johansen ND, Christensen SH, et al. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. N Engl J Med. 2026;394:138-151. doi:10.1056/NEJMoa2509810.

Background

Respiratory syncytial virus (RSV) can cause severe winter respiratory illness in older adults, but randomized trial evidence on preventing hospitalization has been limited.

Patients

131,276 adults in Denmark aged 60 years or older. No formal exclusions; routine vaccine contraindications (e.g., severe allergy to components or acute illness on vaccination day) applied.

Intervention

Single dose of bivalent RSV prefusion F protein vaccine.

Control

No RSV vaccine.

Outcome

Primary: hospitalization for RSV-related respiratory tract disease. Secondary: hospitalization for RSV-related lower respiratory tract disease; hospitalization for respiratory tract disease from any cause; serious adverse events.

Follow-up Period

From 14 days after the scheduled visit until May 31, 2025 (one winter season).

Results

Outcome RSV vaccine No vaccine Vaccine effectiveness (95% CI) Approx. NNT
Hospitalization for RSV-related respiratory tract disease (primary) 3/65,642 18/65,634 83.3% (42.9 to 96.9) ~4,374
Hospitalization for RSV-related lower respiratory tract disease 1/65,642 12/65,634 91.7% (43.7 to 99.8) ~5,963
Hospitalization for respiratory tract disease from any cause 284/65,642 335/65,634 15.2% (0.5 to 27.9) ~1,285
CI = confidence interval; NNT = number needed to treat (approximate, based on trial-period risks).
Primary analyses were intention-to-treat. Serious adverse events within 6 weeks were similar (2.1% vaccine vs 2.4% control).

Limitations

RSV-related hospitalizations were very rare, so estimates are based on few events and absolute benefit per person was small (large NNT). RSV testing in routine care was limited, which may have missed RSV-related cases. Open-label design and single-country (Denmark) setting may limit generalizability.

Funding

Pfizer; sponsor helped design/statistics, not trial conduct or data analysis.

Clinical Application

Offer this RSV vaccine to older adults to reduce RSV-related hospitalization; counsel that individual absolute benefit is small, but population benefit may be meaningful.

Top Journal Rankings - March 2026

6 abstracts scored across 7 criteria. Click any article to expand criterion scores.
1. 6.2
Self-management of male urinary symptoms: qualitative findings from a primary care trial.
Overall: Highly relevant qualitative primary-care evidence suggesting a structured self-management booklet is valued and may improve patient experience, but the abstract lacks quantitative effectiveness and harms data, limiting confidence in the size of benefit and immediate practice change.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Addresses first-line self-management for male LUTS in general practice, using interviews drawn from a 30-site primary care trial and offering concrete suggestions for GP workflows (language, follow-up after PSA testing, booklet distribution).
Validity, Bias Control & Precision 5.0
Appropriate qualitative methods (semi-structured interviews, thematic analysis) and multi-site sampling, but findings are inherently subjective, based on purposive selection, and provide no quantitative effect estimates or precision.
Patient-Oriented Outcomes 6.0
Focuses on patient-experienced symptoms, anxiety, and quality of life, which are patient-important; however outcomes are reported narratively without standardized measurement or prespecified quantitative endpoints in the abstract.
Magnitude of Net Benefit 4.0
Many men valued the booklet and reported improved symptoms and quality of life with reduced anxiety, but the abstract provides no quantified benefit, no systematic harms assessment, and notes some found it unrewarding.
Implementability & Practicality 8.0
A self-help booklet and tailored self-management guidance are low-complexity interventions that can be integrated into routine primary care, with the main barrier described as clinical time/pressure rather than technical requirements.
Practice-Changing Potential 5.0
Provides actionable insights (avoid dismissive language, ensure LUTS follow-up post-PSA, promote self-management resources), but as a qualitative report it mainly informs implementation and patient/clinician perspectives rather than proving outcome improvement.
2. 5.3
Effect of Initiating HPV Vaccination Before Age 11 on HPV Vaccination Completion.
Overall: This retrospective primary-care–relevant study suggests age-related differences in HPV series completion, but limited methodological and effect-size reporting and reliance on a process outcome reduce confidence in the size and certainty of benefit.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
HPV vaccination timing and series completion are routine, high-frequency preventive care decisions in primary care, including family medicine and pediatrics.
Validity, Bias Control & Precision 4.0
Retrospective analysis with limited methodological detail (data source, inclusion/exclusion, confounder adjustment, missingness) and incomplete reporting of precision (no confidence intervals/p-values shown), increasing risk of bias and uncertainty.
Patient-Oriented Outcomes 3.0
The main outcome is vaccine series completion, which is a process measure; the abstract does not report downstream patient outcomes such as HPV infection, dysplasia, cancer, or adverse events.
Magnitude of Net Benefit 4.0
An association is reported (OR 2.802 for completion in ages 11–14 vs other groups), but absolute differences, harms, and the specific effect of initiating before age 11 are not clearly quantified, limiting assessment of clinical net benefit.
Implementability & Practicality 7.0
Earlier initiation of an existing vaccine series is feasible in routine outpatient workflows, though the referenced multi-component, culturally tailored program may require additional resources not described in the abstract.
Practice-Changing Potential 5.0
Supports a plausible strategy (earlier initiation) for a common preventive gap, but the observational design and limited effect reporting make it more hypothesis-supporting than definitively practice-changing.
3. 4.8
Consultations with locum doctors in UK general practice: longitudinal analysis of electronic health records.
Overall: A large, primary-care–focused EHR analysis that credibly describes locum consultation patterns and regional trends, but it is observational and does not address patient outcomes or demonstrate a direct clinical benefit that would change practice.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Directly studies UK general practice consultations across many practices over 12 years, addressing a common real-world primary care staffing and service-delivery issue.
Validity, Bias Control & Precision 7.0
Large retrospective EHR cohort (914 practices) with multilevel mixed-effects modeling supports precision and handling of clustering, but observational design limits causal inference and residual confounding/measurement limitations remain.
Patient-Oriented Outcomes 1.0
Reports workforce/consultation patterns rather than patient-important clinical outcomes (no morbidity, mortality, function, quality of life, or patient experience outcomes presented).
Magnitude of Net Benefit 2.0
No intervention is tested and no benefits/harms to patients are quantified; findings are descriptive (percent of consultations by locums) without direct clinical outcome impact.
Implementability & Practicality 6.0
Results are readily interpretable for planning and benchmarking locum use, but they do not provide a concrete, actionable clinical workflow change for day-to-day practice.
Practice-Changing Potential 4.0
May influence workforce policy discussions by showing higher locum contribution and regional trends, but provides limited direct guidance likely to change individual clinical practice.
4. 4.2
Understanding persistent GP turnover using work and personal characteristics: a retrospective observational study.
Overall: Highly relevant to primary care workforce sustainability, but as a retrospective association study without reported effect sizes or patient outcomes, it offers limited certainty and limited immediately actionable guidance beyond highlighting potential intervention targets.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Directly addresses GP workforce turnover and job satisfaction in English general practice using national data, a highly relevant primary-care systems issue.
Validity, Bias Control & Precision 4.0
Retrospective observational design with regression adjustment limits causal inference; the abstract does not report effect sizes, confidence intervals, or robustness checks, reducing confidence/precision despite a reasonable sample (n=2403).
Patient-Oriented Outcomes 4.0
Outcomes are mainly clinician/job-related (autonomy, belonging, competence, job and life satisfaction, working hours) and practice turnover; patient health outcomes are not assessed.
Magnitude of Net Benefit 2.0
The study reports associations rather than testing an intervention, and provides no quantitative effect estimates in the abstract to judge clinical or practical impact or trade-offs.
Implementability & Practicality 3.0
Findings suggest potential targets for retention interventions, but no specific, actionable intervention, resource requirements, or implementation pathway is evaluated.
Practice-Changing Potential 3.0
Supports the idea that lower job satisfaction correlates with persistent turnover, but without tested solutions or quantified effects, it is more hypothesis-generating than immediately practice- or policy-changing.
5. 4.2
Evaluation of the Need for Comprehensive Care for Patients with Cystic Fibrosis.
Overall: A single-center retrospective EMR study identifies incomplete PCP integration and lower vaccination rates among adults with cystic fibrosis lacking a PCP listing, but limited design rigor and lack of patient-outcome or intervention data constrain actionable, practice-changing conclusions.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 6.0
Addresses a real outpatient primary-care gap (PCP engagement, preventive screening, immunizations) but in a high-acuity, specialty-managed cystic fibrosis population from an adult CF clinic, limiting broad generalizability.
Validity, Bias Control & Precision 4.0
Retrospective, single-center EMR review (n=115) with descriptive comparisons; likely confounding (patients with/without a listed PCP may differ) and limited precision reporting (p-values given for vaccines but no effect sizes or confidence intervals).
Patient-Oriented Outcomes 4.0
Includes potentially patient-important care processes (vaccinations, cancer screening) but the primary outcome is PCP identification in the EMR and other endpoints are largely process/physiologic measures rather than direct morbidity, hospitalization, or quality-of-life outcomes.
Magnitude of Net Benefit 2.0
Does not test an intervention or quantify clinical benefit; reports lower influenza and pneumococcal vaccination rates without a PCP, but provides no absolute differences, downstream health outcomes, or harms/burdens to estimate net benefit.
Implementability & Practicality 6.0
The implied action (better integrating PCPs into CF care and improving preventive care delivery) is feasible in principle, but the abstract does not specify a practical workflow, resources, or implementation strategy to achieve it.
Practice-Changing Potential 3.0
Highlights a care gap and suggests coordination improvements, but observational single-site findings without an evaluated solution or patient-outcome impact are unlikely to change practice on their own.
6. 3.9
A Retrospective Analysis of Soft Tissue Point-of-Care Ultrasound (POCUS) in Primary Care.
Overall: A relevant primary-care descriptive study showing common soft-tissue ultrasound findings and delays, but it is retrospective, lacks patient-oriented outcomes, and does not demonstrate that POCUS changes outcomes or reduces harms.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Directly examines soft-tissue ultrasound ordering patterns from a Family Medicine practice and highlights common outpatient diagnostic questions that are relevant to primary care workflows.
Validity, Bias Control & Precision 4.0
Retrospective, single-practice descriptive analysis without a comparator group; limited ability to control bias or establish causal effects, though basic counts and wait-time distribution are clearly reported (n=168).
Patient-Oriented Outcomes 1.0
Reports imaging findings, follow-up recommendations, and time-to-completion; it does not measure patient-important outcomes such as symptom resolution, complications, functional status, or satisfaction.
Magnitude of Net Benefit 2.0
No intervention is tested and no benefits/harms are quantified; any net benefit of POCUS is suggested rather than demonstrated, aside from documenting delays to radiology ultrasound.
Implementability & Practicality 6.0
Implications (expanded POCUS training) are potentially feasible in primary care where ultrasound is available, but the abstract provides no concrete protocol, training dose, resource needs, or implementation outcomes.
Practice-Changing Potential 3.0
Generates hypotheses about training priorities (lipomas/lymph nodes/cysts) but provides no evidence that changing practice improves diagnostic accuracy, reduces downstream testing, or improves outcomes.
Score Guide: 9-10 Exceptional 7-8 Strong 5-6 Moderate 3-4 Weak 1-2 Poor
Showing top 10 of 6

How It Works

1

Sign Up with Google

Create your account in seconds using your Google account. No passwords to remember.

2

Receive Email Summaries

Get AI-curated clinical summaries delivered to your inbox three times per week (Monday, Wednesday, Friday).

3

Find the Best New Articles

Our interactive article rankings allow you to find the best articles, tailored to you.

Ready to Stay Current?

Sign Up